title: Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.
abstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV. The use of a combination of a serotonin 5-HT3 receptor antagonist, dexamethasone and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy. Palonosetron, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class. Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV. Rolapitant and netupitant are other NK1 receptor antagonists that are currently in phase III clinical trials. Despite the control of emesis, nausea has not been well controlled by current agents. Olanzapine, a US-FDA approved antipsychotic, has emerged in recent trials as an effective preventative agent for CINV, as well as a very effective agent for the treatment of breakthrough emesis and nausea. Clinical trials using gabapentin, cannabinoids and ginger have not been definitive regarding their efficacy in the prevention of CINV. Additional studies are necessary for the control of nausea and for the control of CINV in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.
authors: Indiana University School of Medicine, 1234 Notre Dame Avenue, South Bend, IN 46617, USA. navari.1@nd.edu
authors: Rudolph M
authors: RM
authors: Navari
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D064729:Neurokinin-1 Receptor Antagonists; D044406:Receptors, Serotonin, 5-HT3 / Q000627:therapeutic use; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists; D044406:Receptors, Serotonin, 5-HT3; D058831:Serotonin 5-HT3 Receptor Antagonists
references: J Clin Oncol. 2011 Nov 1;29(31):4189-98
references: 21947834
references: Support Care Cancer. 2011 Aug;19(8):1217-25
references: 20574663
references: Curr Opin Investig Drugs. 2008 Jul;9(7):774-85
references: 18600583
references: Lancet. 2003 May 17;361(9370):1703-5
references: 12767738
references: J Clin Oncol. 2011 Apr 10;29(11):1495-501
references: 21383291
references: Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):239-49
references: 11420092
references: Expert Opin Investig Drugs. 2008 Jan;17(1):85-95
references: 18095921
references: Eur J Pharmacol. 2010 Jan 25;626(2-3):193-9
references: 19836386
references: Gan To Kagaku Ryoho. 1999 Jul;26(8):1163-70
references: 10431583
references: Support Care Cancer. 2007 May;15(5):497-503
references: 17103197
references: J Clin Oncol. 2005 Feb 20;23(6):1289-94
references: 15718327
references: Ann Oncol. 2010 May;21(5):1083-8
references: 20080830
references: Support Care Cancer. 2010 Apr;18(4):423-31
references: 19568773
references: Support Care Cancer. 2012 Jul;20(7):1507-14
references: 21808994
references: Expert Opin Investig Drugs. 2007 Dec;16(12):1977-85
references: 18042005
references: J Support Oncol. 2011 Sep-Oct;9(5):188-95
references: 22024310
references: Support Care Cancer. 2009 May;17(5):563-72
references: 19005687
references: Br J Hosp Med. 1997 Nov 5-18;58(9):442-5
references: 9619205
references: Support Care Cancer. 2007 Nov;15(11):1293-1300
references: 17436025
references: Support Care Cancer. 2012 Jul;20(7):1471-8
references: 21822913
references: Neuropsychopharmacology. 1996 Feb;14(2):87-96
references: 8822531
references: Cancer Invest. 2000;18(2):163-73
references: 10705879
references: Support Care Cancer. 2012 Jul;20(7):1479-89
references: 21818642
references: Ann Oncol. 2010 May;21 Suppl 5:v232-43
references: 20555089
references: Lancet Oncol. 2009 Feb;10(2):115-24
references: 19135415
references: J Clin Oncol. 2006 Sep 20;24(27):4472-8
references: 16983116
references: Support Care Cancer. 2012 Mar;20(3):601-6
references: 21465325
references: Support Care Cancer. 2006 Apr;14(4):354-60
references: 16450086
references: Science. 2005 Oct 14;310(5746):329-32
references: 16224028
references: Ann Oncol. 2004 Feb;15(2):330-7
references: 14760130
references: J Clin Oncol. 2005 Apr 20;23(12):2822-30
references: 15837996
references: J Clin Oncol. 2012 Nov 10;30(32):3998-4003
references: 22915652
references: Br J Cancer. 2006 Apr 10;94(7):1011-5
references: 16552437
references: J Clin Oncol. 2006 Jun 20;24(18):2932-47
references: 16717289
references: Gan To Kagaku Ryoho. 1996 Mar;23(4):477-81
references: 8678501
references: Drugs. 2000 Jun;59(6):1297-315
references: 10882164
references: Ann Pharmacother. 2003 Sep;37(9):1276-86
references: 12921512
references: J Exp Clin Cancer Res. 2009 Sep 23;28:131
references: 19775450
references: Support Care Cancer. 2005 Jul;13(7):529-34
references: 15700131
references: Ann Oncol. 2006 Sep;17(9):1441-9
references: 16766588
references: Clin J Pain. 2009 Mar-Apr;25(3):185-92
references: 19333167
references: Curr Med Res Opin. 2007 Mar;23(3):533-43
references: 17355735
references: Ann Oncol. 2003 Oct;14(10):1570-7
references: 14504060
references: Support Care Cancer. 2013 Jun;21(6):1655-63
references: 23314603
references: Psychosomatics. 1999 Sep-Oct;40(5):438-43
references: 10479950
references: Support Care Cancer. 2007 Nov;15(11):1285
references: 17375339
references: Neurosci Res. 1992 Aug;14(3):166-79
references: 1331921
references: J Clin Oncol. 2003 Nov 15;21(22):4077-80
references: 14559888
references: Drugs. 2009;69(5):515-33
references: 19368415
references: Future Oncol. 2010 Jul;6(7):1073-84
references: 20624119
references: Drugs. 2009;69(13):1853-78
references: 19719336
references: J Clin Oncol. 2009 Nov 10;27(32):5363-9
references: 19805683
references: J Clin Psychiatry. 2001;62 Suppl 7:22-31
references: 11346192
references: Pediatr Blood Cancer. 2011 Feb;56(2):234-8
references: 20842754
references: Eur J Cancer. 2005 Jun;41(9):1278-85
references: 15939263
references: Am J Physiol. 1994 Oct;267(4 Pt 2):R974-83
references: 7524372
references: Eur J Pharmacol. 2001 Nov 2;430(2-3):341-9
references: 11711053
references: Int J Clin Pract. 2012 Aug;66(8):753-757
references: 22805267
references: Drugs. 2000 Sep;60(3):533-46
references: 11030465
references: J Natl Compr Canc Netw. 2007 Jan;5(1):51-9
references: 17239326
references: Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1607-14
references: 19929449
references: Lancet Oncol. 2009 Jun;10(6):549-58
references: 19428297
references: Support Care Cancer. 2005 Feb;13(2):104-8
references: 15549426
references: J Support Oncol. 2006 Sep;4(8):403-8
references: 17004515
references: Cancer. 2004 May 15;100(10):2261-8
references: 15139073
references: Support Care Cancer. 2004 Aug;12(8):550-4
references: 15232725
references: Cancer Invest. 2004;22(3):383-8
references: 15493359
references: Lancet Oncol. 2005 Oct;6(10):765-72
references: 16198982
references: Cancer. 2003 Dec 1;98(11):2473-82
references: 14635083
references: J Support Oncol. 2003 Jul-Aug;1(2):89-103
references: 15352652
references: Support Care Cancer. 2003 Mar;11(3):156-61
references: 12618925
references: J Clin Pharmacol. 2007 Jul;47(7):834-40
references: 17525168